Results 141 to 150 of about 33,699 (271)

Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids. [PDF]

, 2015
BACKGROUND: Poorly controlled asthma often leads to preventable exacerbations that require additional medications, as well as unscheduled hospital and clinic visits.Long-acting beta2-agonists (LABA) are commonly given to adults with asthma whose symptoms
Aalbers, Aaronson, Adams, Adams, Anderson, Barnes, Berger, Bijl-Hofland, Brown, Brozek, Bumbacea, Cates, Cates, Cowie, Crane, Dorinsky, Dorinsky, Ducharme, Ducharme, Ernst, FitzGerald, FitzGerland, Fowler, Godard, Harrison, Hoare, Ind, Johnston, Juniper, Koenig, Koenig, Lipworth, Liu, Nathan, Nathan, Nelson, Nelson, Obase, Paggiaro, Papi, Reddel, Salpeter, Self, Shamsul, Slankard, Tattersfield, Wilding, Zangrilli   +47 more
core   +1 more source

Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD

International Journal of COPD, 2019
Masakazu Ichinose,1 Yasushi Fukushima,2 Yoshikazu Inoue,3 Osamu Hataji,4 Gary T Ferguson,5 Klaus F Rabe,6 Nobuya Hayashi,7 Hiroshi Okada,7 Mami Takikawa,7 Eric Bourne,8 Shaila Ballal,9 Kiernan DeAngelis,10 Magnus Aurivillius,11 Colin Reisner,9 Paul ...
Ichinose M, Fukushima Y, Inoue Y, Hataji O, Ferguson GT, Rabe KF, Hayashi N, Okada H, Takikawa M, Bourne E, Ballal S, DeAngelis K, Aurivillius M, Reisner C, Dorinsky P   +14 more
doaj  

Enantioselective Chromatographic Analysis of Formoterol Fumarate using Chiral Mobile Phase Additives and Achiral Core-Shell Column

, 2020
Pranav Pathak, Krishnapriya Mohanraj
openalex   +1 more source

FUNCTIONAL RESPIRATORY IMAGING ASSESSMENT OF BUDESONIDE/GLYCOPYRROLATE/FORMOTEROL FUMARATE AND GLYCOPYRROLATE/FORMOTEROL FUMARATE METERED DOSE INHALERS IN PATIENTS WITH COPD [PDF]

Chest, 2020
M. van den Berge, Jan De Backer, Cedric Van Holsbeke, Wilfried De Backer, Roopa Trivedi, Martin Jenkins, Paul Dorinsky, Magnus Aurivillius   +7 more
openaire   +1 more source

Effectiveness of combined use of formoterol fumarate tablets and interventional bronchoscopy in the treatment of central airway tumor

, 2023
Dandan Fu, Li-na Duan, Chi Zhang, Fengjiao Liu, Xingyi Chen, Rong Liu, Li Zheng   +6 more
openalex   +2 more sources

Clinical Effectiveness of Budesonide/Formoterol Fumarate Easyhaler® for Patients with Poorly Controlled Obstructive Airway Disease: a Real-World Study of Patient-Reported Outcomes [PDF]

, 2018
Lilla Tamási, Mária Szilasi, Gabriella Gálffy   +2 more
openalex   +1 more source

Exploring the Psycological Effects of Formoterol Fumarate and Budesonide Inhaler: A Case Study on Induced Depression

Journal of Drug Delivery and Therapeutics
A patient with a longstanding history of chronic obstructive pulmonary disease (COPD) presented with significant weight loss, loss of appetite, fatigue, and sleep disturbance persisting for 15 days, alongside a rapid weight loss of 15 kg in 10 days ...
R. Subashini, R. Priyadharshini, S. Aishwarya, V. Hema   +3 more
semanticscholar   +1 more source

Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD

International Journal of COPD, 2018
Edward M Kerwin,1 Thomas M Siler,2 Samir Arora,3 Patrick Darken,4 Earl St Rose,4 Colin Reisner4,5 1Clinical Research Institute of Southern Oregon, Medford, OR, USA; 2Midwest Chest Consultants, St Charles, MO, USA; 3Aventiv Research, Columbus, OH, USA ...
Kerwin EM, Siler TM, Arora S, Darken P, St Rose E, Reisner C   +5 more
doaj  

Network meta-analysis of the efficacy and safety of monoclonal antibodies and traditional conventional dichotomous agents for chronic obstructive pulmonary disease

Frontiers in Medicine
IntroductionMonoclonal antibodies (mAbs) against cytokines and chemokines or their receptors promise to be a potential therapeutic option to address chronic obstructive pulmonary disease (COPD).
Yu Xiong, Yu Xiong, Yu Xiong, Jia-qiang Hu, Hui-lin Tang, Zhi-xia Zhao, Zhi-xia Zhao, Li-hong Liu, Li-hong Liu   +8 more
doaj   +1 more source

Formoterol Dry-Powder Inhalation ??? Novartis/SkyePharma

Drugs in R & D, 2004
In November 1998, Novartis Pharma of Switzerland and SkyePharma PLC of the UK signed an agreement to jointly develop a new formulation of the beta(2)-adrenoceptor agonist formoterol (Foradil). The new product, Foradil Certihaler, utilises a multidose dry-powder inhaler (MDPI or MDDPI) device, SkyeHaler, developed by SkyePharma.
openaire   +2 more sources